Zhengye Biotechnology Holding Limited (ZYBT)

ZYBT Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	189.75	211.65	260.27	214.07
Revenue Growth (YoY)	-25.23%	-18.68%	21.58%	-
Cost of Revenue	84.42	91.84	107.27	89.45
Gross Profit	105.33	119.81	153	124.62
Selling, General & Admin	66.91	66.63	63.56	58.86
Research & Development	11.19	11.9	13.42	11.37
Operating Expenses	74.75	74.82	86.72	72.16
Operating Income	30.58	44.99	66.28	52.47
Interest Expense	-4.32	-4.42	-2.84	-1.05
Interest & Investment Income	0.42	0.31	0.11	0.11
Other Non Operating Income (Expenses)	3.05	2.89	0.81	1.62
EBT Excluding Unusual Items	29.72	43.76	64.36	53.15
Asset Writedown	-	-	-0.45	-0.08
Pretax Income	29.72	43.76	63.91	53.07
Income Tax Expense	5.56	6.25	8.17	6.6
Earnings From Continuing Operations	24.16	37.51	55.74	46.47
Minority Interest in Earnings	-3.88	-6.05	-9.01	-7.51
Net Income	20.29	31.46	46.74	38.96
Net Income to Common	20.29	31.46	46.74	38.96
Net Income Growth	-53.70%	-32.69%	19.96%	-
Shares Outstanding (Basic)	46	46	46	46
Shares Outstanding (Diluted)	46	46	46	46
EPS (Basic)	0.44	0.69	1.02	0.85
EPS (Diluted)	0.44	0.69	1.02	0.85
EPS Growth	-53.70%	-32.69%	19.96%	-
Free Cash Flow	46.9	40.79	-9.99	12.75
Free Cash Flow Per Share	1.03	0.89	-0.22	0.28
Gross Margin	55.51%	56.61%	58.78%	58.22%
Operating Margin	16.11%	21.25%	25.47%	24.51%
Profit Margin	10.69%	14.86%	17.96%	18.20%
Free Cash Flow Margin	24.72%	19.27%	-3.84%	5.96%
EBITDA	53.9	68.9	85.08	68.48
EBITDA Margin	28.41%	32.55%	32.69%	31.99%
D&A For EBITDA	23.32	23.91	18.8	16.01
EBIT	30.58	44.99	66.28	52.47
EBIT Margin	16.11%	21.25%	25.46%	24.51%
Effective Tax Rate	18.69%	14.29%	12.79%	12.44%
Advertising Expenses	-	2.54	2.58	2.23

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q